Haploidentical hematopoietic stem cell transplantation in pediatric and adolescent patients: A study of the Spanish hematopoietic stem cell transplantation group (GETH)

Ochoa-Fernández, Bárbara; Galán-Gómez, Víctor; Mestre, Carmen; González‐Vicent, Marta; Pascual, Antonia; Alonso, Laura; Regueiro, Alexandra; Plaza, Mercedes; Hurtado, José María Pérez; Benito, Ana; Fuster, José Luís; Bueno, David; Mozo, Yasmina; Vicário, José L.; Balas, A.; Sisinni, Luisa; Heredia, Cristina Díaz de; Pérez‐Martínez, Antonio

doi:10.1016/j.medcli.2022.01.009

Cited by 3 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We saw an evolution from the first period when, according to local protocols, some patients underwent autologous HSCT as a consolidation treatment, a practice that has decreased in the most recent period ( Table 2 ). On the other hand, we see an increase in the use of haploidentical HSCT, according to what has been reported in our country with the acquisition of experience and graft manipulation techniques in the recent decades ( 18 ). The 5-year OS for the patients who underwent HSCT was 60.4% vs. 18.5% for the non-transplanted patients, similar to that reported in INTERFANT-99 (a 4-year disease-free survival of 50% for HSCT vs. 37% for chemotherapy alone) ( 9 ).…”

Section: Discussionmentioning

confidence: 57%

Younger age and induction failure predict outcomes in infant leukemia: 30 years of experience in a tertiary center

et al. 2023

Self Cite

View full text Add to dashboard Cite

ObjectivesThis study aimed to evaluate the characteristics and outcomes of infant patients with leukemia.MethodsA retrospective analysis was conducted in a cohort of 39 patients diagnosed with infant leukemia from 1990 to 2020 who underwent treatment at the pediatric hemato-oncology department of a tertiary hospital in Madrid, Spain.ResultsOf the 588 diagnosed cases of childhood leukemia, 39 (6.6%) cases were infant leukemia. The 5-year event-free survival and the 5-year overall survival were 43.6% (SE 4.1) and 46.5% (SD 24.08), respectively. In a univariate analysis, a younger age at diagnosis was associated with poorer outcomes (p = 0.027), as was induction failure (p = 0.0024). Patients treated with hematopoietic stem cell transplantation had better outcomes than non-transplanted patients (p = 0.001); however, the group comparisons that exclude patients who were unable to undergo transplantation due to refractoriness/relapse or death during treatment showed no significant differences.ConclusionsThe main risk factors that affected survival in our study were an age younger than 6 months and a poor response to induction therapy. It is important to identify poor prognostic factors in this population in order to seek different approaches that could improve outcomes.

show abstract

Section: Discussionmentioning

confidence: 57%